The safety of omalizumab therapy in a patient with severe persistent allergic asthma and hepatitis C.
Antonicelli
Leonardo
L
Stagnozzi
Giorgia
G
Giuliodoro
Simona
S
Abbruzzetti
Alessandra
A
Massaccesi
Chiara
C
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000402:Airway Obstruction; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage; D001249:Asthma / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D016174:Hepacivirus / Q000254:growth & development / Q000276:immunology* / Q000502:physiology; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis* / Q000503:physiopathology; D006801:Humans; D007167:Immunotherapy; D016898:Interferon-alpha / Q000008:administration & dosage; D008168:Lung / Q000201:enzymology* / Q000473:pathology / Q000821:virology; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012129:Respiratory Function Tests; D019562:Viral Load; D014774:Virulence
D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D016898:Interferon-alpha; D000069444:Omalizumab